A. Ulmann, The development of mifépristone : A pharmaceutical drama in three acts, J Am Med Womens Assoc, vol.55, issue.3, pp.117-137, 2000.

J. Khan, B. Becker, and L. Maclsaa, The efficacy of medical abortion: a meta-analysis, Contraception, vol.61, issue.1, pp.29-40, 2000.
DOI : 10.1016/S0010-7824(99)00115-8

E. Schaff, Mifépristone : ten years later. Contraception, pp.1-7, 2010.

. Haute-autorité-de-santé, Interruption volontaire de grossesse par méthode médicamenteuse, Déc, vol.Argumentaire, pp.1-58, 2010.

A. Vilain and M. Mouquet, Les interruptions volontaires de grossesses en, 2012.

A. Vilain, Les interruptions volontaires de grossesses en 2007, Etudes et résultats

A. Vilain, Les établissements et professionnels réalisant des IVG. Etudes et résultats, Déc, vol.712, pp.1-6, 2009.

P. Svendsen, C. Rorbye, T. Vejborg, and L. Nilas, Comparison of gemeprost and vaginal misoprostol in first trimester mifepristone induced abortion. Contraception, pp.28-32, 2005.

H. Honkonen, G. Piaggio, V. Hertzen, and H. , WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.. II: Side effects and women's perceptions, BJOG: An International Journal of Obstetrics and Gynaecology, vol.307, issue.7, pp.715-740, 2004.
DOI : 10.1016/S0010-7824(99)00119-5

V. Hertzen, H. Huong, N. Piaggio, and G. , Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial, BJOG: An International Journal of Obstetrics & Gynaecology, vol.19, issue.10
DOI : 10.1111/j.1471-0528.2010.02636.x

N. Pharma, Etude aMaYa : étude épidémiologique portant sur les modalités d'administration des thérapeutiques utilisées dans les IVG médicamenteuse en pratique courante dans les centres d'orthogénie

P. Faucher and D. Hassoun, 1 -Mécanismes d'action des médicaments In : Interruption volontaire de grossesse médicamenteuse

A. Guiochon-mantel, Antiprogestatifs : mécanisme d'action, Reprod Hum Horm, vol.12, issue.3, pp.248-53, 1999.

P. Ashok, A. Templeton, P. Wagaarachchi, and G. Flett, Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases, BJOG: An International Journal of Obstetrics and Gynaecology, vol.99, issue.2, 2002.
DOI : 10.1016/S0010-7824(00)00090-1

P. Ashok, G. Peney, G. Flett, and A. Templeton, An effective regimen for early medical abortion: a report of 2000 consecutive cases, Human Reproduction, vol.13, issue.10, pp.2962-2967, 1998.
DOI : 10.1093/humrep/13.10.2962

. Haute-autorité-de-santé, Niveau de preuve et gradation des recommandations de bonne pratique. 2013 Avr, pp.1-92

M. Provansal, R. Mimari, B. Gregoire, A. Agostini, X. Thition et al., Interruption volontaire de grossesse m??dicamenteuse ?? domicile et ?? l???h??pital??: ??tude d???efficacit?? et d???acceptabilit??, Gyn??cologie Obst??trique & Fertilit??, vol.37, issue.11-12, pp.11-12, 2009.
DOI : 10.1016/j.gyobfe.2009.07.016

S. Gaudu, M. Crostc, and L. Esterlec, Results of a 4-year study on 15 447 medical abortions provided by privately practicing general practitioners and gynecologists in

S. Cameron, A. Glasier, H. Dewart, A. Johnstone, and A. Burnside, Telephone follow-up and self-performed urine pregnancy testing after early medical abortion: a service evaluation, Contraception, vol.86, issue.1, pp.67-73, 2012.
DOI : 10.1016/j.contraception.2011.11.010

A. Vilain, Les femmes ayant recours à l'IVG : diversité des profils des femmes et des modalités de prise en charge, Revue Française des Affaires Sociales, vol.1, pp.117-165, 2011.

E. Raymond, C. Shannon, M. Weaver, and B. Winikoff, First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review, Contraception, vol.87, issue.1, p.2013
DOI : 10.1016/j.contraception.2012.06.011

T. Middleton, E. Schaff, and S. Fielding, Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period, Contraception, vol.72, issue.5
DOI : 10.1016/j.contraception.2005.05.017

B. Winikoff, I. Dzuba, and M. Creinin, Tow distinct oral routes of misoprostol in mifepristone medical abortion : a randomized controlled trial, Obstet Gynecol, 2008.

E. Chong, T. Tsereteli, N. Nguyen, and B. Winikoff, A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion, Contraception, vol.86, issue.3
DOI : 10.1016/j.contraception.2011.12.012

J. Chai, C. Wong, and P. Ho, A radomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days' gestation. Contraception, pp.480-485, 2013.

B. Winikoff, I. Dzuba, and E. Chong, Extending outpatient medical abortion services through 70 days of gestational age, Obstet Gynecol, vol.120, pp.1070-1076, 2012.

M. Gallo, S. Cahill, L. Castleman, and E. Mitchell, A systématique review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation

K. Coyaji, U. Krishna, and S. Ambardekar, Are two doses of misoprostol after mifepristone for early abortion better than one ? BJOG, pp.271-279, 2007.

R. Kulier, N. Kapp, A. Gülmezoglu, G. Hofmeyr, L. Cheng et al., Medical methods for first trimester abortion, Cochrane Database Syst Rev, vol.11, p.2855, 2011.
DOI : 10.1002/14651858.cd002855.pub4

I. Spitz, W. Bardin, L. Benton, and A. Robbins, Early Pregnancy Termination with Mifepristone and Misoprostol in the United States, New England Journal of Medicine, vol.338, issue.18, pp.1241-1248, 1998.
DOI : 10.1056/NEJM199804303381801

R. Sitruk-ware, Mifépristone and misoprostol sequential regimen side effects, complications and safety. Contraception, pp.48-55, 2006.
DOI : 10.1016/j.contraception.2006.03.016

G. Acharya, M. Haugen, A. Brathen, I. Nilsen, and J. Maltau, Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting, Acta Obstetricia et Gynecologica Scandinavica, vol.7, issue.4
DOI : 10.1016/S0010-7824(01)00266-9

A. Cowett, L. Cohen, E. Lichtenberg, and C. Stika, Ultrasound Evaluation of the Endometrium After Medical Termination of Pregnancy, Obstetrics & Gynecology, vol.103, issue.5, Part 1, pp.871-876, 2004.
DOI : 10.1097/01.AOG.0000124782.69622.48

C. Fiala, P. Safar, M. Bydgeman, and K. Gemzell-danielson, Verifying the effectiveness of medical abortion; ultrasound versus hCG testing, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.109, issue.2, pp.190-195, 2003.
DOI : 10.1016/S0301-2115(03)00012-5

E. Wiebe, Pain control in medical abortion, International Journal of Gynecology & Obstetrics, vol.36, issue.3, pp.275-80, 2001.
DOI : 10.1016/S0020-7292(01)00453-2

D. Noannoa, L. Westhoff, C. Fielding, S. Schaff, and E. , Timing of pain and bleeding after mifepristone-induced abortion, Contraception, vol.62, issue.6, pp.305-314, 2000.
DOI : 10.1016/S0010-7824(00)00181-5

S. Suhonen, M. Tikka, S. Kivinen, and T. Kauppila, Pain during medical abortion: predicting factors from gynecologic history and medical staff evaluation of severity, Contraception, vol.83, issue.4
DOI : 10.1016/j.contraception.2010.08.006

F. L. Nguyen, interruption volontaire de grossesse en ville: spécificités et difficultés rencontrées dans la pratique de ville dans le cadre de l'IVG par méthode médicamenteuse

C. Fiala, B. Winikoff, L. Helström, M. Hellborg, and K. Gemzell-danielsson, Acceptability of home-use of misoprosotol in medical abortion. Contraception, pp.387-92, 2004.

E. Schaff, L. Stadalius, S. Eisinger, and P. Franks, Vaginal misoprostol administered at home after mifepristone (RU486) for abortion, J Fam Pract, vol.44, issue.4, pp.353-60, 1997.
DOI : 10.1001/jama.284.15.1948

T. Ngo, M. Park, H. Shakura, and C. Freea, Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review, Bulletin of the World Health Organization, vol.89, issue.5, pp.360-70, 2011.
DOI : 10.2471/BLT.10.084046

H. Kallner, C. Fiala, O. Stephansson, and K. Gemzell-danielsson, Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days, Human Reproduction, vol.25, issue.5, pp.1153-57, 2010.
DOI : 10.1093/humrep/deq037

H. Bracken, R. Dabash, and G. Tsertsvadza, A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: a prospective comparative open-label trial, Contraception, vol.89, issue.3, pp.181-187, 2014.
DOI : 10.1016/j.contraception.2013.10.018

URL : http://doi.org/10.1016/j.contraception.2013.10.018

R. Henshaw, S. Naji, I. Russell, and A. Templeton, Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment., BMJ, vol.307, issue.6906, pp.714-721, 1993.
DOI : 10.1136/bmj.307.6906.714

C. Moreau, J. Trussell, J. Desfreres, and N. Bajos, Medical versus surgical abortion: The importance of women's choice, Contraception, vol.82, issue.2, pp.224-233, 2011.
DOI : 10.1016/j.contraception.2010.04.107

J. Tang, N. Kapp, M. Dragoman, D. Souza, and J. , WHO recommendations for misoprostol use for obstetric and gynecologic indications, International Journal of Gynecology & Obstetrics, vol.194, issue.(2), pp.186-195, 2013.
DOI : 10.1016/j.ijgo.2012.12.009

A. Faundes, The combination of mifepristone and misoprostol for the termination of pregnancy, International Journal of Gynecology & Obstetrics, vol.99, issue.4, pp.1-4, 2011.
DOI : 10.1016/j.ijgo.2011.07.013

G. Beucher, P. Dolley, G. Carles, F. Salaun, I. Asselin et al., Misoprostol??: utilisation hors AMM au premier trimestre de la grossesse (fausses couches spontan??es, interruptions m??dicales et volontaires de grossesse), Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.43, issue.2
DOI : 10.1016/j.jgyn.2013.11.007

W. Clark, C. Shannon, and B. Winikoff, Misoprostol as a single agent for medical termination of pregnancy. (page consultée le 23 UpToDate ?, 2014.